ERBB2 and breast cancer: Of 186 consecutive patients with early-stage HER2 + BC, as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization, who received NAC plus HER2-targeted agents, 167 with an available biopsy specimen were eligible for inclusion.